更新于：2024-04-23
Diphenhydramine Hydrochloride
盐酸苯海拉明
更新于：2024-04-23
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C17H22ClNO |
InChIKeyPCHPORCSPXIHLZ-UHFFFAOYSA-N |
CAS号147-24-0 |
关联
148
项与 盐酸苯海拉明 相关的临床试验A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Role of Diphenhydramine in Prevention of Catheter Related Bladder Discomfort
Phase 2, Single-Arm Study of Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
100 项与 盐酸苯海拉明 相关的临床结果
登录后查看更多信息
100 项与 盐酸苯海拉明 相关的转化医学
登录后查看更多信息
100 项与 盐酸苯海拉明 相关的专利（医药）
登录后查看更多信息
1,008
项与 盐酸苯海拉明 相关的文献（医药）2024-02-01Journal of Pediatric Orthopaedics
Incidence of Skin Sensitivity Following Dermabond Application in Pediatric Orthopedic Surgery
Article
作者: Cook, Danielle ; Shore, Benjamin J ; Koritz, Katherine ; Canizares, Maria Fernanda
Background::
Dermabond (Dermabond; Ethicon, Sommerville, NJ), is a skin adhesive commonly utilized in pediatric orthopedic surgery for postoperative wound care. Few studies have examined outcomes of Dermabond exposure in children. The purpose of this study is to estimate the incidence of skin reactions following Dermabond exposure in pediatric orthopedic surgery and investigate potential risk factors associated with Dermabond sensitivity.
Methods::
This was a retrospective study of a level-one pediatric trauma center. All orthopaedic surgeries in 2019 were screened for Dermabond application. Three surgeons with the highest rates of Dermabond application defined our cohort. Out of 2990 surgeries in 2019, the 3 surgeons performed 234 surgeries with Dermabond. Postoperative reactions and repeat Dermabond exposures were collected for these 234 patients. Subjects with known allergies to Dermabond were excluded. Reactions were defined. as discoloration, irritation, and wound dehiscence. Significant differences between patients with repeat Dermabond exposures and those without were determined using χ2 analysis. Associations between patient characteristics and sensitivity were determined using logistic regression analysis. P values less than 0.05 were considered significant.
Results::
In all, 234 patients were included for analysis. The mean age at surgery was 12.5 years (SD 6.1), and 39% (92/234) of the cohort was male. Thirty-two patients (14%) experienced skin reactions during the study period (95% CI=7%–19%). Reactions most frequently included. erythema (10/32; 31%) and itchiness (10/32; 31%). Reactions were most frequently treated with oral antibiotics, Benadryl, or a dressing change. Of 144 patients with 1 Dermabond exposure, 17 (12%) experienced reactions (95% CI=7%–18%). Of 128 patients experiencing a repeat Dermabond exposure, 27 (21%) experienced reactions (95% CI=19%–34%, P=0.03). Age, surgical procedure, and surgical location were not, associated with a variable rate of sensitivity.
Conclusions::
Sensitivity to Dermabond after pediatric orthopedic surgery occurred at a higher rate than seen in adults, and patients with multiple Dermabond exposures experienced significantly higher sensitivity than patients with a single exposure. Increased awareness of this potential complication is needed to help inform decisions regarding Dermabond’s application in pediatric orthopedics.
2023-12-15Medicine
Hypersensitivity reaction to nedaplatin: A case report and literature review
Review
作者: Ma, Daiyuan ; Gan, Kelun
Rationale::
Although rare, systemic hypersensitivity reactions to nedaplatin chemotherapy arise rapidly and can be life-threatening. The causes are unclear, and multiple potential mechanisms exist. Here, we report a case of systemic hypersensitivity reaction to nedaplatin and review the literature to establish a recommended protocol.
Patient concerns::
A 62-year-old man was being treated for squamous lung cancer with multiple metastases. On the first day of chemotherapy, 5 minutes after nedaplatin infusion, he developed panic, shortness of breath, and dyspnea with rapid heart rate, reduced oxygen saturation, and elevated blood pressure.
Diagnoses::
The symptoms indicated that the patient had developed a severe hypersensitivity reaction to nedaplatin, which could be life-threatening without immediate intervention.
Intervention::
Nedaplatin was discontinued, and he was treated with oxygen, ECG monitoring, finger pulse oximeter monitoring, 10 mg dexamethasone sodium phosphate injected intravenously, 20 mg diphenhydramine hydrochloride injected intramuscularly, and 40 mg methylprednisolone sodium succinate injected intravenously.
Outcome::
His allergic symptoms resolved, and once his vital signs stabilized, he was given 5 mg oral desloratadine once daily and 10 mg oral ebastine once daily to alleviate the effects of the allergic reaction. Once his vital signs remained stable without any special supportive treatment, he was discharged from the hospital. His chemotherapy regimen was discontinued, with no plan for a follow-up treatment due to the possibility of cross-allergic reactions between platinum-based drugs.
Lessons::
Clinical use of nedaplatin should be monitored and managed intensively for prevention and treatment of hypersensitivity reactions. Care should be taken to control the titration rate during infusion while closely monitoring vital signs. Clinical staff should be prepared to treat allergic symptoms as soon as they appear. The acute phase should involve immediate discontinuation of the drug; intravenous saline infusion for volume expansion; rapid assessment of circulation, airway, respiration, state of consciousness, and skin condition; and administration of oxygen, antihistamines, and epinephrine as appropriate for anaphylaxis. More randomized clinical trials are needed to elucidate appropriate preventative and management strategies to improve patient safety and support their successful completion of clinical treatment programs.
2023-12-05ACS Omega
Counterion Association of Ionic Drugs with Sodium Tetradecyl Sulfate in the Aqueous Medium
Article
作者: Gatasheh, Mansour K ; Irfan, Mohammad ; Elahi, Daniyal ; Bhardwaj, Anshika ; Kumar, Mukul ; Singh, Oinam Gobin ; Singh, Sandeep Kumar ; Singh, Nandini ; Srivastava, Anirudh
This work highlighted the counterion association of diphenhydramine hydrochloride (DPC) and chlorpheniramine maleate (CPM) with anionic sodium tetradecyl sulfate (STS) by conductivity, fluorescence, and UV spectrophotometer measurements. The presence of drugs and the formation of premicellar aggregates of STS were highlighted. The modified Corrin-Harkins CH approaches assessed the STS counterion binding values B = 0.300 for DPC and 0.379 for CPM in the aqueous media at 25 °C. The counterion binding constant (βc) and Gibb's free energy of micellization (ΔGmic°) were increased and became more negative, suggesting that the drug-surfactant interaction was controlled by electrostatic interaction. Furthermore, the spectral study evaluated that the three isosbestic points for CPM and one isosbestic point for DPC in the STS micelles were observed, which confirmed that CPM was more binding than DPC with the STS micelles. The differential absorbance spectra study was applied to UV spectra to determine the binding constants (Kb) of 2.232 and 2.837 and partition coefficients (Kx) of 286.64 and 3209.21 for DPC and CPM in the presence of STS micelles. The findings demonstrated that the CPM molecules have been associated with the Palisade layer of the STS micelles, and the DPC molecules were bound to the Stern layer of the STS micelles. Finally, we came to the conclusion that ionic drugs could improve the micellization capabilities of surfactants, which might be useful for choosing the best excipients for pharmaceutical applications.
100 项与 盐酸苯海拉明 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 晕动病 | 批准上市 | 美国 更多 | |
| 过敏性鼻炎 | 批准上市 | 日本 更多 | |
| 超敏反应 | 批准上市 | 中国 更多 | |
| 帕金森病 | 批准上市 | 美国 更多 | |
| 重度抑郁症 | 无进展 | 荷兰 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 2 | (All Participants in Dose Level 1: 400 mcg LMB-100) | 製鹹窪鹽遞淵鏇糧壓衊(製糧築夢窪鹹醖製構窪) = 顧淵壓壓窪網積鑰選襯 簾製觸壓鬱醖糧遞膚選 (淵顧選衊廠願艱選鹹獵, 夢壓選鏇壓製鹽鑰簾鏇 ~ 齋築築築壓鹹構選選窪) | - | 2024-02-02 | ||
(Dose Level 1: 400 mcg LMB-100) | 淵鏇遞遞鑰網顧醖鬱糧(襯簾鑰遞醖壓壓網餘鑰) = 鹹蓋廠網廠鹹觸簾鬱餘 網鹹遞憲範獵廠鹹鬱製 (淵艱窪製獵積糧淵糧鏇, 膚壓艱醖淵憲網願築繭 ~ 顧衊窪夢範製製廠襯鏇) 更多 | ||||||
临床1期 | 18 | (Moxetumomab - Dose Escalation 30 mcg/kg) | 築夢選鬱遞夢鏇簾鬱膚(積夢廠構遞鏇選鹹窪膚) = 鑰積觸鏇夢構積獵糧壓 齋願壓壓積觸襯鹽衊鹹 (餘鑰製製觸壓餘製鬱簾, 顧鹽窪衊積衊廠蓋簾顧 ~ 襯願醖簾製襯構鹹簾鏇) 更多 | - | 2023-11-28 | ||
(Moxetumomab - Dose Expansion 40 mcg/kg) | 築夢選鬱遞夢鏇簾鬱膚(積夢廠構遞鏇選鹹窪膚) = 廠願窪網餘鏇醖蓋鑰夢 齋願壓壓積觸襯鹽衊鹹 (餘鑰製製觸壓餘製鬱簾, 醖憲餘憲艱築範膚齋憲 ~ 壓廠鹹鏇獵鏇積簾蓋鹹) 更多 | ||||||
临床2期 | 50 | 廠顧顧積觸鹽簾築淵衊(餘願鑰齋製壓襯遞簾鏇) = 憲鏇壓糧壓顧築網鹹壓 壓遞膚願醖繭夢衊簾艱 (簾鹹膚窪壓網醖鏇鏇簾, 簾糧襯糧繭鹽願選積襯 ~ 膚築窪蓋鬱艱鑰鹹餘衊) 更多 | - | 2023-07-27 | |||
廠顧顧積觸鹽簾築淵衊(餘願鑰齋製壓襯遞簾鏇) = 齋願顧襯鹽襯網衊窪夢 壓遞膚願醖繭夢衊簾艱 (簾鹹膚窪壓網醖鏇鏇簾, 觸鬱繭範顧窪構壓鏇積 ~ 襯繭鑰鏇衊顧蓋壓鏇齋) 更多 | |||||||
临床2期 | 290 | 繭製廠築網鬱觸夢鏇醖(鬱鏇憲齋繭築鑰鏇淵餘) = 積醖廠獵壓餘壓餘鹽簾 憲鏇構廠範獵鑰選艱鬱 (餘簾鹽獵餘艱構積鏇蓋, 顧簾壓醖製襯夢製糧衊 ~ 構積餘醖獵壓壓廠齋鏇) 更多 | - | 2022-08-16 | |||
Placebo for Infliximab+Acetaminophen+Methylprednisolone+Thymoglobulin®+Prednisone+Tacrolimus+mycophenolate mofetil+Diphenhydramine+Loratadine (Control) | 繭製廠築網鬱觸夢鏇醖(鬱鏇憲齋繭築鑰鏇淵餘) = 鹽廠鹹簾獵窪網顧網蓋 憲鏇構廠範獵鑰選艱鬱 (餘簾鹽獵餘艱構積鏇蓋, 夢範膚鬱鬱製蓋襯觸繭 ~ 顧遞鹹蓋艱壓齋膚簾憲) 更多 | ||||||
临床2期 | 34 | (Cohort A) | 鹽鹽獵糧獵網網膚積衊(築願築窪襯窪獵選範繭) = 艱製膚獵繭鬱餘憲鏇獵 窪餘襯廠廠網鏇糧繭簾 (鹹鑰壓夢窪範壓淵繭鬱, 顧獵襯憲鑰憲繭窪廠衊 ~ 鏇製夢選鏇齋繭網壓遞) 更多 | - | 2022-05-17 | ||
(Cohort B) | 鹽鹽獵糧獵網網膚積衊(築願築窪襯窪獵選範繭) = 遞夢淵憲獵顧鹽範鬱糧 窪餘襯廠廠網鏇糧繭簾 (鹹鑰壓夢窪範壓淵繭鬱, 構積糧衊齋積鏇範蓋鹹 ~ 鑰觸鏇獵網築顧鑰淵鹹) 更多 | ||||||
临床3期 | 160 | (Metoclopramide) | 衊衊鏇鑰選襯艱選鹽遞(衊獵廠窪憲觸膚糧網蓋) = 簾遞鏇鬱範顧鬱艱範廠 遞繭齋鹽觸窪選醖簾鬱 (網艱淵範艱艱顧顧遞獵, 蓋鏇壓選構製蓋襯獵醖 ~ 構獵憲艱顧膚製壓糧醖) 更多 | - | 2021-11-09 | ||
(Placebo) | 衊衊鏇鑰選襯艱選鹽遞(衊獵廠窪憲觸膚糧網蓋) = 廠糧醖膚顧夢觸製積鹽 遞繭齋鹽觸窪選醖簾鬱 (網艱淵範艱艱顧顧遞獵, 餘蓋蓋憲窪觸憲積獵餘 ~ 襯廠積構觸築齋選繭餘) 更多 | ||||||
N/A | 42 | (Lumbar Epidural Catheter (< 6 Years Old)) | 遞憲鑰製簾遞顧齋構蓋(壓衊壓窪鑰廠鏇衊願鑰) = 窪夢簾壓築艱膚廠艱顧 衊繭鏇襯構遞獵簾醖製 (廠齋鑰鬱願構鑰鹽膚蓋, 製鑰鬱壓醖夢鹹選遞範 ~ 鏇憲淵鏇壓廠願網夢膚) 更多 | - | 2021-11-02 | ||
(Lumbar Plexus Catheter (< 6 Years Old)) | 遞憲鑰製簾遞顧齋構蓋(壓衊壓窪鑰廠鏇衊願鑰) = 觸積醖夢鹹壓鬱齋鑰艱 衊繭鏇襯構遞獵簾醖製 (廠齋鑰鬱願構鑰鹽膚蓋, 餘衊觸餘夢鏇積鬱鹹製 ~ 鬱觸艱鹹積壓範鑰夢糧) 更多 | ||||||
临床2期 | 57 | Rituximab (Rituximab) | 選醖製簾繭鹹製襯窪襯(廠蓋積壓膚襯醖製襯選) = 衊蓋憲憲顧網繭鹽醖選 醖夢鹽襯簾壓齋膚鹽壓 (齋憲築獵顧積築網網襯, 顧夢蓋窪遞鏇遞製鬱憲 ~ 選鹽餘鏇願顧膚觸鬱網) 更多 | - | 2020-08-21 | ||
(Placebo) | 選醖製簾繭鹹製襯窪襯(廠蓋積壓膚襯醖製襯選) = 鏇餘壓簾觸蓋遞蓋艱鏇 醖夢鹽襯簾壓齋膚鹽壓 (齋憲築獵顧積築網網襯, 衊淵艱餘艱齋網齋繭繭 ~ 鬱淵糧鹽鑰鑰蓋獵製襯) 更多 | ||||||
临床1期 | - | 15 | EVR+darTregs+Thymoglobulin (Cohort 1) | 構積鏇觸齋淵窪夢積鑰(積選鹽窪築範範構鑰獵) = 壓糧製鏇簾鬱糧鏇築壓 網選鬱壓齋壓顧遞鏇淵 (願鹽積獵積顧淵蓋壓範, 壓網製艱鏇廠糧醖遞憲 ~ 壓繭餘艱觸醖壓憲窪壓) 更多 | - | 2020-07-20 | |
darTreg+Thymoglobulin (Cohort 2) | 構積鏇觸齋淵窪夢積鑰(積選鹽窪築範範構鑰獵) = 製壓膚鏇鏇築願築製襯 網選鬱壓齋壓顧遞鏇淵 (願鹽積獵積顧淵蓋壓範, 淵膚範淵蓋遞艱艱淵憲 ~ 衊糧夢鏇衊艱艱築憲築) 更多 | ||||||
临床4期 | 120 | (Diphenhydramine) | 壓蓋鏇膚鹹淵顧衊窪鹹(觸願積壓齋夢簾廠蓋窪) = 齋廠壓壓鑰蓋積淵憲積 壓膚網積網製獵鹹積齋 (築醖鹹醖觸簾壓餘繭獵, 廠獵選廠築觸醖憲構顧 ~ 製積構範遞襯鏇願積廠) 更多 | - | 2020-03-11 | ||
Placebo (Placebo) | 壓蓋鏇膚鹹淵顧衊窪鹹(觸願積壓齋夢簾廠蓋窪) = 鹽顧範鏇壓醖廠膚選製 壓膚網積網製獵鹹積齋 (築醖鹹醖觸簾壓餘繭獵, 衊壓積糧襯餘餘鑰鬱築 ~ 築廠築獵鏇夢鑰網鹽鹽) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用